Jared Holz, Mizuho, joins ‘Fast Money’ to talk Novo Nordisk’s recent climb.
Source link
Trending
- RTX, GE Aerospace expect more than $1 billion tariff impact
- U.S. still Europe’s most trusted ally, Polish finance minister says
- Wells Fargo downgrades UPS, says tariffs to hit shipping volume
- IMF slashes U.S. growth forecast by nearly one percentage point
- No recovery in sight for struggling cocoa market, Lindt CEO says
- GE Aerospace, Amazon, 3M and more
- Lockheed Martin (LMT) Q1 earnings
- Bath & Body Works has a major tariff advantage. Here’s why
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
